FIELD: biotechnology.
SUBSTANCE: combination for the treatment of cancer is proposed, containing a monoclonal antibody to progastrin and an inhibitor of an immune control point. The inhibitor of an immune control point is an antibody to PD1. A pharmaceutical composition containing the specified combination is also proposed.
EFFECT: invention provides increased therapeutic efficiency against cancer.
14 cl, 2 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| ANTI-CD39 ANTIBODIES, COMPOSITIONS CONTAINING ANTI-CD39 ANTIBODIES AND METHODS OF APPLICATION OF ANTI-CD39 ANTIBODIES | 2018 |
|
RU2795348C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| ELEMENTS THAT BIND TO IL-1 BETA | 2013 |
|
RU2711118C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
